© 2018 Miraculo Inc. All Rights Reserved
High-CBD Cannabis extract may have superior therapeutic properties than single-molecule cannabidiol according to a new study from Israel. This goes against pharmaceutical orthodox that claims that botanical compounds are somehow cruder and of a lower quality than laboratory produced compounds.
The study is titled “Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol,” directly challenges the recent ‘Bell Curve’ findings that claim that a medium dose of CBD has a higher therapeutic effect than low and high doses.
The study found that laboratory-produced, single-molecule CBD did indeed create the bell-shaped response curve. Which meant after a certain dose the effectiveness of the CBD reduced. This bell curve represents a serious limitation to the clinical use of CBD.
The aim of the Israeli study was to find if there was another source of CBD that can avoid the inflexible bell curve response. The study focused on a CBD-rich strain of medical cannabis called “Avidekel”. This strain contains a very low level of THC, the chemical associated with the ‘high’ generated by cannabis.
The researchers extracted a high-CBD oil from the Avidekel. The oil had a staggeringly high level of CBD, coming in at nearly 20% of its total mass. The extract was then given to mice to measure its anti-inflammatory and pain killing effects.The scientists also dosed some mice with pure CBD for comparative purposes.
The pure CBD displayed the bell curve for its effectiveness predicted by earlier research. The Avidekel extract, however, showed different results. The plant-based extract showed a dose-dependent response. In other words, the more that the scientists administered, the higher the therapeutic effects.
This makes the Avidekel-based extract much more useful for clinical use.